Fiscal Year Ending March 2026 Q3 Financial Summary [Japanese GAAP] (Consolidated)

Summary of Business Results

For the cumulative third quarter of the fiscal year ending March 2026, net sales totaled 114,475 million yen (5.4% YoY increase), operating income was 9,200 million yen (13.0% YoY increase), ordinary income was 9,628 million yen (14.0% YoY increase), and net income attributable to owners of parent for the quarter was 6,557 million yen (24.6% YoY increase). The main reasons for the increase in sales and profit were steady new customer acquisitions and progress in pricing optimization initiatives. Each segment, including clinical testing, food hygiene, medical information systems, and other businesses, recorded higher sales.

Summary of Financial Position

As of the end of the third quarter of the fiscal year ending March 2026, total assets amounted to 176,860 million yen (a decrease of 646 million yen from the previous fiscal year-end), net assets were 130,130 million yen (a decrease of 3,642 million yen from the previous fiscal year-end), and the equity ratio stood at 71.1% (down 1.8 points from the previous fiscal year-end). While current assets decreased, current liabilities increased. Capital surplus and retained earnings declined, whereas treasury stock increased.

Dividend Status

The annual dividend for the fiscal year ending March 2026 is forecasted at 60 yen at year-end, totaling 120 yen for the full year, which is the same amount as the previous fiscal year. There has been no revision to the latest dividend forecast.

Revision to Full-Year Earnings Guidance

The consolidated full-year earnings guidance for the fiscal year ending March 2026 has been revised to net sales of 149,000 million yen (0.7% increase from the previous forecast), operating income of 10,000 million yen (11.1% increase), ordinary income of 10,500 million yen (9.4% increase), and net income attributable to owners of parent of 7,000 million yen (16.7% increase). The factors contributing to higher profits include steady new customer acquisitions, progress in pricing optimization, and increased depreciation expenses due to the start of operations at the new BML General Research Institute building.